These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is there a future for antiviral fusion inhibitors? Berkhout B; Eggink D; Sanders RW Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966 [TBL] [Abstract][Full Text] [Related]
4. Entry inhibitors and their use in the treatment of HIV-1 infection. Haqqani AA; Tilton JC Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872 [TBL] [Abstract][Full Text] [Related]
5. Updating the use of synthetic peptides as inhibitors of HIV-1 entry. Gómara MJ; Haro I Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277 [TBL] [Abstract][Full Text] [Related]
6. Targeting HIV attachment and entry for therapy. Strizki J Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410 [No Abstract] [Full Text] [Related]
7. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies. Mostashari Rad T; Saghaie L; Fassihi A Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572 [TBL] [Abstract][Full Text] [Related]
8. [Viral entry as therapeutic target. Current situation of entry inhibitors]. Arenzana-Seisdedos F Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215 [TBL] [Abstract][Full Text] [Related]
9. The HIV entry inhibitors revisited. Leonard JT; Roy K Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 entry into cells. Copeland KF Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):107-12. PubMed ID: 18221139 [TBL] [Abstract][Full Text] [Related]
11. Progress in targeting HIV-1 entry. Ryser HJ; Flückiger R Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193 [TBL] [Abstract][Full Text] [Related]
12. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches. Malik T; Chauhan G; Rath G; Murthy RS; Goyal AK Drug Deliv; 2017 Nov; 24(1):608-621. PubMed ID: 28240046 [TBL] [Abstract][Full Text] [Related]
14. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533 [TBL] [Abstract][Full Text] [Related]
15. Discovery of natural mouse serum derived HIV-1 entry inhibitor(s). Wei M; Chen Y; Xi J; Ru S; Ji M; Zhang D; Fang Q; Tang B Acta Virol; 2016; 60(4):404-409. PubMed ID: 27928921 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Markovic I; Clouse KA Curr HIV Res; 2004 Jul; 2(3):223-34. PubMed ID: 15279586 [TBL] [Abstract][Full Text] [Related]
17. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs. Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting HIV-1 entry with fusion inhibitors. Baldwin CE; Sanders RW; Berkhout B Curr Med Chem; 2003 Sep; 10(17):1633-42. PubMed ID: 12871113 [TBL] [Abstract][Full Text] [Related]